INTRODUCTION
Psoriasis vulgaris (referred to hereafter as psori asis) is a chronic inflammatory skin disease affecting 2-3% of the white US population. 1,2 Psoriasis often develops in early adulthood between the ages of 15 and 30 years, although individuals of all ages can be affected. The plaques of thick, scaly skin observed in the psori atic lesion reflect a number of biological changes, including the reduction in the transit time of a keratinocyte from basal cell to desquamated cell (from 4-6 weeks to only a few days). Moreover, a large number of activated immune cells in the psoriatic dermis produce a complex cytokine milieu not found in normal skin.
Up to 30% of patients with psoriasis also develop psoriatic arthritis (PsA). 3 These patients complain of chronic joint pain, fatigue and restriction of mobility, and experience a reduced quality of life compared to normal indivi duals. 3 Some patients with PsA can also have an increased prevalence of cardiovascular disease and its associated risk factors compared with matched controls. 4 The same is true for patients with psoriasis, and those with severe disease could have a higher prevalence of cardiovascular risk factors than those with milder disease. 5 Here, we briefly review the clinical features of PsA and the treatment modalities currently available. We also describe newly identified genetic associ ations that confer susceptibility to both psoriasis and PsA, which begin to explain the fundamental basis of the biological alterations found in these diseases and highlight pathways to be targeted for the development of novel therapies.
GENETIC AND ENVIRONMENTAL CONTRIBUTIONS
PsA is a highly heritable disease. The recur rence risk (λ S ; risk to siblings:risk in the general population) of PsA is greater than 27, 6 which is far higher than for psoriasis (between 4 and 11). 7 Heritability is also greater for PsA than for some other autoimmune conditions, such as rheumatoid arthritis (RA), primary Sjögren's syndrome or thyroid disease. 8 The prevalence of psoriasis is 19 times higher among first degree relatives of probands with PsA compared with the general population. 9 Psoriatic lesions can be triggered by a large number of factors in genetically susceptible indivi duals, including physical injury to the skin (the 'Koebner' response), administration of interferon (IFN) or other inflammationinducing stimuli, rapid withdrawal of immunosuppressive drugs, and infection (often systemic) with streptococcus or other bacteria. 10 By contrast, the triggers for PsA are not as clear, although viral triggers have been suggested. 11 
CLINICAL FEATURES OF PSORIATIC ARTHRITIS
In 1973, Moll and Wright 12 defined PsA as an inflammatory peripheral arthritis and/or spondy litis associated with psoriasis and a negative serology test for rheumatoid factor. Since then, the wide spectrum of clinical presentations of PsA has resulted in the development of classification criteria to help distinguish PsA from other forms of inflammatory, arthritis such as RA. 13 These criteria include equal sex distribution, asymmetric arthritis particularly involving the distal interphalangeal joints, arthritis mutilans, spondyloarthropathy and a higher incidence of nail involvement than uncomplicated psoriasis. 14 In approximately 80% of patients who develop psoriasis, arthritis follows by a mean of 10 years. 14, 15 Joint manifesta tions can also present before or at the same time as skin lesions. The arthritis is, in most cases, oligoarticular, but can involve more joints over time, resulting in a symmetric and polyarticular destructive arthritis. 15 A predominantly spinal variant can present with asymmetric sacroiliitis and discontinuous spinal involvement, resem bling ankylosing spondylitis (AS). Enthesitis can help distinguish PsA from RA and osteoarthritis: this common feature of PsA is evident on plain radiography and MRI as periostitis, new bone formation and erosions. 16 
CURRENT THERAPIES FOR PSORIATIC ARTHRITIS
The symptoms of mild PsA are often successfully alleviated by treatment with NSAIDs or local intra articular injections of corticosteroids. 17 Neither of these modalities, however, can arrest the develop ment of structural joint damage. 18 Extensive or aggressive disease requires more potent therapy with, for example, traditional DMARDs, including methotrexate and sulfasalazine. 17 Methotrexate has been widely used to treat severe psoriasis since the 1960s; 19 its broad antiinflammatory effect, mediated by adenosine, can neutralize neutrophils, T cells and macrophages, which are all key players in the pathogenesis of psoriasis and PsA. 20 Ciclosporin, which is a potent inhibitor of Tcell activation and cytokine production, is effective for the rapid control of both psoriasis and PsA. 19 By contrast, targeting specific Tcell costimulatory molecules with biological response modifiers, such as alefacept, a fusion protein of IgG 1 and human lymphocyte functionassociated antigen (LFA)3 (also known as CD58), is effec tive for the treatment of psoriasis but not PsA. 21 Likewise, efalizumab, a humanized monoclonal antibody against LFA1 expressed by T cells, is effective in psoriasis 22 but is not significantly more effective than placebo in the treatment of PsA. 23 In some cases, treatment of psoriasis with efalizumab has even been shown to exacerbate or trigger the onset of PsA. 24 Three tumor necrosis factor (TNF) antago nists-adalimumab, etanercept and infliximabhave been approved by the FDA for the treatment of PsA. Significant numbers of patients treated with these agents achieve excellent clinical results. 25, 26 Multiple clinical trials have also demonstrated the efficacy of TNF blockade for the treatment of psoriasis. 27 Etanercept exerts its effect in psoriasis by inhibiting the production of inflammatory cytokines by myeloid dendritic cells, thus reducing the activity of type 17 Thelper (T H 17) cells-the newly described pathogenic lineage of effector CD4 + T cells-and the levels of their secreted cytokines. 27 TNF antagonists can also downregulate the differentiation and activation of osteoclasts, 26 thus reducing bone destruction in PsA. Paradoxically, TNF blockade can also induce or worsen psoriasis, perhaps owing to unopposed production of type 1 IFN by plasmacytoid dendritic cells. 28 Blockade of the p40 subunit shared by interleukin (IL)12 and IL23 also results in a dramatic and prolonged clinical response to psoriasis. 29 Collectively, these data imply a pivotal role for dendriticcell and Tcell interactions via TNF and the IL23-T H 17 axis in the pathogenesis of psoriasis and potentially of PsA, as discussed further below.
PATHOGENIC CLUES FROM GENETIC ANALYSES
The efficacy of immunomodulatory therapies for the treatment of both psoriasis and PsA implicates shared immunologic mechanisms in the pathogenesis of these diseases. Affected skin and synovium are both characterized by marked vascularity and robust mononuclear inflammatory infiltration that includes dendritic cells, activated T cells and tissue macrophages; 30 multiple genetic risk factors related to the develop ment or maintenance of these immune cells are being identified.
Approaches to identifying the genetic causes of disease depend on whether the genetic changes arise from rare mutations or common variation. The identification of rare variants responsible for Mendelian traits can be accomplished by linkage analysis followed by positional cloning, provided that a sufficient number of affected individuals and their family members are available for statis tical analyses. By contrast, common variation associated with widespread diseases, such as psoriasis and PsA, can be identified using genetic association studies. Although highly plausible candidate genes for psoriasis and PsA (i.e. those within the major histocompatibility complex (MHC) region and IL12B) have been investigated in this way, 31, 32 improved technologies for use in genomewide association studies have facilitated a genomewide and unbiased approach to gene discovery (Box 1).
Below we present genes and loci associated with PsA. These were originally described in the context of their association with psoriasis, and were then tested for an association with PsA (Table 1 ). The probable contributions of these loci to immunopathology and disease pathogenesis, particularly in the context of joint inflammation, are discussed and illustrated in Figure 1 .
PSORS1 and other HLA antigens
Psoriasis susceptibility 1 (PSORS1) was the first psoriasis susceptibility locus to be mapped to the MHC class I region. The strong association between PSORS1 and HLA-Cw*0602 [33] [34] [35] [36] is esti mated to account for onethird to onehalf of genetic susceptibility to psoriasis. 36 The frequency of HLA-Cw*0602 is also increased among patients with PsA compared with controls 31 (Table 1) and, in patients with PsA, is also associated with an earlier mean age of psoriasis onset (P = 0.003). 31 Genomewide association studies also indi cate that alleles in the HLA class I region are more strongly associated with PsA than are any other loci in the genome. 37 In one report, the single nucleotide polymorphisms (SNPs) most strongly associated with PsA tag HLA-Cw*0602, but also tag the rarer and closelyrelated HLACw*1203 allele. 34 Interestingly, the proteins encoded by HLA-Cw*0602 and HLA-Cw*1203 might be recognized by the same antigen or self peptide, as they are identical in their α2 domains and peptide binding pockets A, D and E. 34 They differ, however, by five amino acids in their α1 domain, which places them in different killer cell immunoglobulinlike receptor (KIR) ligand groups. As other independent studies point to HLA-Cw*0602 as the lone PSORS1 risk allele, 33 functional studies are needed to resolve this discrepancy and to conclusively rule out SNPs that affect the expression of HLAC alleles or other skinspecific genes in this region, such as corneodesmosin and coiledcoil αhelical rod protein 1.
Early studies of PsA associations with MHC alleles were generally performed with small numbers of patients, but nonetheless deserve some discussion. HLA-B27 is associated with spinal involvement, whereas HLA-B38 and HLA-B39 are associated with peripheral poly arthritis. 38 These last two alleles are highly corre lated with HLA-Cw*1203; therefore, this early finding could have arisen from the association of HLA-Cw*1203 with PsA. The presence of the RA 'shared epitope' HLA-DRB1 in the HLA class II region is reported to be associated with radio logical erosions in PsA. 39 Moreover, HLA-B39 alone, HLA-B27 in the presence of HLA-DR7, and HLA-DQw3 in the absence of HLA-DR7, are all reported to confer an increased risk for disease progression. 39 Conversely, HLA-B22 is reported to protect against disease progression. 38 Patients with both HLA-Cw6 and HLA-DRB1*07 alleles are reported to have a lesssevere course of Box 1 Genome-wide association studies.
These approaches search for associations of a disease with single nucleotide polymorphisms, which are variations in the DNA sequence that exists in two forms (alleles) in a population. The International HapMap project 90 has selected many such markers (at least 500,000) throughout the genome as representative of their surrounding sequences. When an 'association' exists between a single nucleotide polymorphism and a disease, the frequency of the alleles differs between affected individuals and healthy controls. The marker is usually not the 'cause' of the disease trait, but it identifies the general locale of the offending alteration.
noGraleS ET AL. february 2009 vol 5 no 2 www.nature.com/clinicalpractice/rheum arthritis than patients with either HLA-Cw6 or HLA-DRB1*07 alone. 40 Whether some of these associations are due to linkage disequilibrium within the MHC region, thus reflecting a predis posing haplotype harboring a different risk factor, or whether the variants themselves are truly causative, is not clear.
TNF polymorphisms are of interest, given the success of antiTNF agents in the treatment of psoriasis and PsA. The TNF polymorphisms associated with psoriasis and PsA, such as those in the TNF promoter region at positions -238 and -308, have been demonstrated to be due to linkage disequilibrium with HLA-Cw*0602. 41 TNF*-857T, however, might represent a risk factor for PsA that is independent of the PSORS1 allele. 41 In the case of PsA susceptibility, genetic inter actions between certain HLA class I alleles and KIRs located on chromosome 19 are described. Natural Killer (NK) cell activity is partially controlled through interactions between KIRs on NK cells and their respective HLA class I ligands. Susceptibility to PsA is strongly associ ated with the presence of KIR2DS1 and/or KIR2DS2 in combination with HLA-Cw ligand group homozygosity, 42, 43 and susceptibility to PsA is proposed to be a function of the overall balance between activating and inhibitory composite KIR-HLA genotypes. 43 Certain combinations of KIRs and HLAB alleles are also associated with slowed AIDS development and a decreased risk of HIV infec tion in exposed, uninfected individuals. 44 These include the combined genotype of KIR3DL1 highexpressing alleles and HLA-B*57, which is associated with PsA. Certain combinations of HLA and KIR alleles are also reported to affect outcomes following infection by other viruses, such as hepatitis B virus, hepatitis C virus and human papilloma virus. 45 It is tempting to speculate that past selection of alleles that confer protection against viral infection led to susceptibility to diseases such as PsA.
The following are genes that have recently been implicated in psoriasis and PsA through genetic analyses (also summarized in Table 1 ).
Genes influencing the IL-23-T H 17 pathway
Susceptibility to both psoriasis and PsA is associ ated with alleles of the IL12p40 (IL12B) and IL23 receptor (IL23R) genes (Table 1) . 32, 37, 46, 47 51 which could result from the direct effect of genetic risk factors in regulatory regions of these genes. The serum level of the IL12/IL23 p40 subunit is also one of the protein markers that can maximally discriminate patients with PsA from controls. 52 T H 17 cells are developmentally and function ally distinct from cells of the classic T H 1 and T H 2 lineages, and are characterized by the produc tion of IL17 and IL22. 53 Similar to the tradi tional T H 1 and T H 2 cells, they are thought to ncprheum_2005_156f1.eps have evolved to provide adaptive immunity to specific classes of pathogens, such as extracellular bacteria. Aberrant T H 17 responses are implicated in a growing list of autoimmune disorders, 54 and the production of both IL17 and IL22 cytokines are increased in psoriatic lesions. 55, 56 These cytokines induce proinflammatory chemo kines, and promote epidermal acanthosis and parakeratosis. 56 However, whether the IL23-T H 17 axis is similarly relevant in triggering joint disease in PsA remains unclear. Activated T cells infiltrate PsAaffected joints in distribution patterns similar to those seen in lesional skin: CD4 + T cells predominate over CD8 + in the dermis 57 and synovial membrane, 58 and CD8 + cells predominate in the epidermis and syno vial fluid; 59 however, the intraarticular levels of T H 17associated cytokines have yet to be established. Lymphocytes and fibroblasts in the synovial fluid from PsA joints can induce osteo clastogenesis and trigger bone resorption and articular damage via the interaction of receptor activator of nuclear factor κB (RANK; also known as TNF receptor superfamily, member 11a) and its ligand (RANKL; also known as TNF superfamily, member 11), TNF and IL7. 60 In addition, in vitro studies have demonstrated that IL23 can induce osteoclastogenesis by a mechanism that is dependent on IL17, TNF and RANKL. 60, 61 Treatment with a humanized monoclonal antibody against the IL12/IL23 p40 subunit can reduce the signs and symptoms of PsA, 62 supporting an important pathogenic role for IL23 in potentiating osteoclasto genesis and exerting a proerosive influence in PsAaffected joints. A region of chromosome 4q27 encoding IL2 and IL21, which is associated with celiac disease, 63 type 1 diabetes, 64 RA 65 and systemic lupus erythematosus, 66 has also been associated with PsA susceptibility in one study (Table 1) . 37 IL2 is a pathogenic cytokine in psoriasis, and the blockade of the IL2 receptor with thera peutic antibodies can resolve the disease in some cases. 67 Together with TGFβ, IL2 is also essen tial for the generation and function of regulatory T (T REG ) cells. 68 IL21 is produced by activated T cells, and influ ences the proliferation of T cells and B cells and the cytolytic activity of NK cells. 69 Importantly, IL21 is also produced by T H 17 cells and is thought to promote and sustain T H 17 differen tiation and IL17 production in an autocrine fashion. 70, 71 The presence of IL21, however, has yet to be demonstrated in psoriatic skin or synovium, and the functional variant(s) from chromosome 4q27 that mediate autoimmunity need to be identified.
Notably, the effects of the genetic associations described above converge on cellular pathways involved in the 'decision' of an antigenstimulated cell to differentiate into either a T H 17 or T REG cell. In mice, TGFβ at low concentrations synergizes with IL6 and IL21 to relieve Foxp3mediated inhibition of RORγt, thereby promoting IL23R expression and favoring T H 17 cell development, 72 a process that is dependent on histone-protein deacetylase activity. 73 Conversely, TGFβ at high concentrations represses IL23R expression and favors the development of T REG cells. 72 The role of T REG cells in PsA has not been described, but it is known that they can suppress RANKL dependent osteoclast formation. 74 The 5q31 locus The 5q31 region harbors the genes encoding IL4, IL13 and IL5, which are upregulated in T cells committed to the T H 2 lineage, 68 and certain alleles that confer susceptibility to a number of inflammatory diseases, including Crohn's disease, asthma and psoriasis. 75, 76 Psoriasisassociated variants, both upstream from IL13 and within SLC22A4 (also known as OCTN1), may confer an increased risk of developing disease independent of Crohn's disease variants. 76 An independent study, however, indicated that the same SLC22A4 variant is associated with both Crohn's disease and PsA. 77 The role of the 5q31 locus in the develop ment of psoriasis, and potentially PsA, is not clear. In an animal model, IL4 prevents the development of arthritis induced by antigens or infectious agents by inducing a switch from a T H 1type to a T H 2type response. 78 IL4 and IL13 also negatively regulate pathways induced by TNF and IFNγ in keratinocytes via the activation of signal transducer and activator of transcription (STAT)6, suppressor of cytokine signaling (SOCS)1 and SOCS3. This activa tion interferes with STAT1 and NFκB signaling, thus inhibiting the induction of βdefensins 4 and 103 (also known as HBD2 and HBD3, respectively). 79 IL4 and IL13 also have a role in the induction of T REG cells from peripheral naive CD4 + T cells. 80 This induction is indepen dent of the presence of TGFβ or IL10, but is dependent on antigenspecific stimulation and B7 costimulation. Psoriasis is also associated with alleles of TNFAIP3 (TNFαinduced protein 3, which encodes a zinc finger/ubiquitinediting enzyme, A20) and with upstream noncoding variants of its partner TNIP1 (which encodes TNFAIP3interacting protein 1 [TNIP1]. 50 The proteins they encode have a role in restricting NFκBdependent signaling and in preventing inflammation. Independent poly morphisms in TNFAIP3 are associated with RA and systemic lupus erythematosus. [81] [82] [83] TNIP1 is upregulated in psoriatic lesions and unaffected skin of patients with psoriasis compared with normal skin from controls, potentially as a result of its upstream noncoding genetic risk factors. 50 The association of TNFAIP3 and TNIP1 with PsA needs to be examined.
Genetic associations requiring further investigation
Another potential avenue to explore in the genetics of PsA is the overlap between AS and PsA, as these two diseases share at least some genetic risk factors (e.g. HLA-B27, IL23R 49 and IL1 84 ). ARTS1, TSHR and FCRL3 are also associ ated with susceptibility to AS. 48 As over 40% of patients with PsA also have spondyloarthritis, patients with combinations of genetic risk factors that are also found in AS patients might belong to a particular subset.
Other similarities between these two diseases regarding the skin and joints are worth exploring. Activated osteoclasts are CD68 + bloodderived, macrophagelike cells that normally exist in an unactivated state on the bone cortex or outer surface. 85 CD68 + CD11c + dendritic cells are also present in the dermal-epidermal junc tion of lesional psoriatic skin and are the main producers of IL20. 86 IL20 production can be stimulated by TNF 86 that is produced by myeloid leukocytes, including dendritic cells and macro phages. Hence, genetic factors that contribute to the differentiation, activation, or down regulation of myeloid cells could be important for the CD68 + osteoclasts in PsA and also for the CD68 + CD11c + dendritic cells in psoriasis.
CONCLUSIONS
The immune system is a tightly regulated network of cells and cytokines, and genetic factors that lead to immune alterations are likely to tip the balance towards inflammation in the skin and synovium of patients with psoriasis and PsA, respectively. Noteworthy genetic associations shared by psoriasis and PsA involve components of the IL23-T H 17 pathway, namely IL23R, IL12B, and potentially IL23A and IL21. As the various subsets of T H cells can counterregulate each other, 87 further analysis of the contribu tions and interactions of different T H cell subsets in PsA is of extreme interest, as is the question of whether they also have a role in osteoclasto genesis. Specific genetic factors that differentiate PsA from psoriasis also need to be identified.
As is seen in psoriasis, with the exception of risk factors encoded by the MHC region, genetic risk factors for PsA generally have odds ratios below 2, and frequently between 1.1 and 1.5. Hence, multiple genes with a low risk effect are likely to be involved in susceptibility to psoriasis and PsA. Similarly, in Crohn's disease, with the exception of IL23R and NOD2, around 30 genes with low odds ratios (generally <1.3) have been identified, and many additional risk factors with even moremodest effect are predicted to predispose individuals to this disease. 88 Many questions remain unanswered that, we hope, genetics can further elucidate. Can we stratify patients into different subpopulations based on genetic risk factors, and tailor therapy to each subpopulation? Which genetic risk factors can predict response to treatment? What role does the environment play in triggering disease? Answering these questions will require much larger patient populations than those studied so far, in addition to wellannotated clinical databases.
KEY POINTS

■
Multiple genes with low risk effects are involved in susceptibility to psoriasis vulgaris and psoriatic arthritis (PsA) ■ Newly uncovered genetic associations shared by psoriasis and PsA implicate components of the IL-23-TH17 pathway in both diseases ■ Given these genetic links, further evaluation of the pathogenic role of the IL-23-TH17 pathway in PsA is warranted 
